Innovating, Validating & Enabling Digital Biomarker & Endpoint Acceptance in CNS

Welcome to the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit

With 3 days of jam-packed content and 24+ digital health experts and clinical innovators speakers, the 2^nd Digital Biomarkers & Clinical Measures in Neuro Summit is biopharma’s can’t-miss meeting for the innovation, validation, and acceptance of digital endpoints in CNS pipelines.

Join 100+ of your digital health and CNS clinical development peers to address the standardization and regulatory acceptance of digital tools and data analysis as endpoints in complex neurological indications, discover novel innovations for objective, sensitive, and non-invasive neurological measures, and ensure internal confidence and scalability with emerging digital technologies.

Uniting Digital Health Biopharma with CNS Clinical Drug Developers to:

Address the Standardization & Regulatory Acceptance of Digital Tools & Data Analysis as Endpoints in Complex Neurological Indications
Discover Novel Innovations for Objective, Sensitive, & Non-Invasive Neurological Measures
Ensure Confidence & Scalability with Emerging Digital Technologies

EVENT GUIDE

Your 24+ World-Class Speaker Faculty Includes:

Matthew Czech

Associate Director, Digital Science

Abbvie

Abhishek Pratap

Head of Data Innovation, Biogen Digital Health

Biogen

Jonas Abdel-Khalik

Senior Digital Health Scientist

Lundbeck

Xiangnan Dang

Director - Engineering

Eli Lilly & Co.

Michal Melamed

Data scientist

Teva Pharmaceuticals

Tairmae Kangarloo

Associate Director, Digital Strategy

Takeda Pharmaceutical Co. Ltd.

VIEW SPEAKERS

Previously Attending Companies Include:

Hear from the Previous Attendees:

"I never expected to make such genuine connections around our shared, deep interest in digital biomarkers, or to learn that I am not alone in the technical, operational, or regulatory challenges I face”

Raul Torres, Principal Data Scientist, Takeda